23andMe offers at-home test for breast cancer gene mutations

The DNA testing company 23andMe has gotten FDA approval to screen for 3 BRCA gene mutations linked to a higher risk of breast cancer. But the test raises some concerns. Katie Nielsen of CBS San Francisco station KPIX reports.
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news

Related Links:

To examine the efficacy of image-guided percutaneous interventions in pain and local tumor control in the treatment of osseous metastases from breast cancer.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific Session 31: You ’re So Hip (MSK) Source Type: research
To describe the hepatotoxicity of radioembolization (RE) for liver metastasis in breast cancer (BC) patients on systemic therapy.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific Session 45: Y-DeLiver (Radioembolization III) Source Type: research
When Tom Shicowich’s toe started feeling numb in 2010, he brushed it off as a temporary ache. At the time, he didn’t have health insurance, so he put off going to the doctor. The toe became infected, and he got so sick that he stayed in bed for two days with what he assumed was the flu. When he finally saw a doctor, the physician immediately sent Shicowich to the emergency room. Several days later, surgeons amputated his toe, and he ended up spending a month in the hospital to recover. Shicowich lost his toe because of complications of Type 2 diabetes as he struggled to keep his blood sugar under control. He wa...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized health Nutrition Source Type: news
Background: Second primary malignancies (SPM) in the lung are not common in breast cancer (BC) patients.EGFR-mutant lung cancer (LC) is a separate molecular subset, and the co-existence ofEGFR-mutant LC and BC has not been explored. We hypothesized thatEGFR-mutant LC patients could have higher rates of primary BC than those withEGFR-wild type (WT).Methods: We collected data on clinical and molecular characteristics and outcomes of female patients with LC and a previous or simultaneous history of primary BC treated in our hospital from 2008 to 2014.Results: Data on treatment, follow-up, andEGFR mutation status were availabl...
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
However, many report feeling uncomfortable or believing they lack the necessary knowledge
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Nursing, Oncology, Radiology, Surgery, Journal, Source Type: news
Publication date: Available online 21 February 2019Source: Journal of the Taiwan Institute of Chemical EngineersAuthor(s): Chih-Hsiang Chang, I-Chi Tsai, Chung-Jen Chiang, Yun-Peng ChaoAbstractThe heterogeneous nature of cancers renders the efficacy of the therapeutic treatment diversified. To address this issue, a theranostic approach was proposed by development of a hybrid peptide for simultaneous diagnosis and therapy of cancer cells. Peptide A was composed of the biotinylation site (BS), the HER2/neu-binding motif, and the dockerin domain (Doc). Peptide B was designed with BS and the cohesin domain (Coh). Individually ...
Source: Journal of the Taiwan Institute of Chemical Engineers - Category: Chemistry Source Type: research
Publication date: Available online 22 February 2019Source: Chinese Chemical LettersAuthor(s): Chao Song, Dan Gao, Tianying Yuan, Yongli Chen, Liping Liu, Xiaowu Chen, Yuyang JiangAbstractCell migration and invasion are critical steps in cancer metastasis, which are the major cause of death in cancer patients. Tumor-associated macrophages (TAMs) and interstitial flow (IF) are two important biochemical and biomechanical cues in tumor microenvironment, play essential roles in tumor progression. However, their combined effects on tumor cell migration and invasion as well as molecular mechanism remains largely unknown. In this ...
Source: Chinese Chemical Letters - Category: Chemistry Source Type: research
Dalton Trans., 2019, Advance Article DOI: 10.1039/C9DT00335E, CommunicationYan Guo, Shuren Zhang, Hao Yuan, Dongfan Song, Suxing Jin, Zijian Guo, Xiaoyong Wang A PtIV prodrug bearing a vascular disrupting agent demonstrates antiangiogenic and antimetastatic potentialities against metastatic triple-negative breast cancer cells. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Dalton Trans. latest articles - Category: Chemistry Authors: Source Type: research
Condition:   Breast Cancer Intervention:   Sponsors:   Peking Union Medical College Hospital;   Peking University Third Hospital;   Beijing Hospital;   Beijing Chao Yang Hospital;   Beijing Zhongguancun Hospital;   Peking University Shouyang Hospital;   Beijing Aerospace Center Hospital;   Beijing Anzhen Community Health  Service Center;   The First Hospital of Tsinghua University;   Sun Yat-sen Hospital,&n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 21 February 2019Source: The Lancet Global HealthAuthor(s): Peter C Rockers, Richard O Laing, Paul G Ashigbie, Monica A Onyango, Carol K Mukiira, Veronika J WirtzSummaryBackgroundNovartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the effect of Novartis Access in Kenya, the first country to receive the programme.MethodsWe did a cluster-randomised controlled trial in eight counties in Kenya. Counties (clusters) were randomly assigned ...
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Health